Methods: Patients with rhinoconjunctivitis with/without asthma induced by birch/tree pollen were treated with a SCIT depot preparation (Birch or Tree-Mix, AVANZ, ALK-Abelló, Hørsholm, Denmark) containing 15% of the allergen content and 50% of the alum content compared with the widely used ALK allergen product for SCIT (Alutard SQ, ALK-Abellò, Hørsholm, Denmark). Therapy was initiated by up-dosing with 5 injections (300, 600, 3.000, 6.000, 15.000 SQ+) in weekly intervals and was continued by maintenance injections of 15.000 SQ+ with 14 and 28 days intervals.
Results: In total 409 patients were documented (Birch: 81, Tree Mix: 328 patients). The effectiveness of the treatment was rated as good or very good by 88.2% of the patients (Birch 85.1%, Tree-Mix 88.8%) and 90.7% by the investigators (Birch 87.2%, Tree-Mix 91.5%). Adverse events were in general mild to moderate local reactions and occurred in 22.7% of the patients mostly at up-dosing (18.8% of patients). Serious adverse events were reported in 5 patients (1.2%). Among them, the causality was rated as 'possible' in 3 patients. Overall the tolerability was assessed as good or very good by 96.8% of the patients (Birch 100.0%, Tree-Mix 96.1%) and 97.1% by the investigators (Birch 98.1%, Tree-Mix 96.6%).
Conclusion: A SCIT product with an optimised allergen/adjuvant ratio (AVANZ) routinely used in the daily practise with 5 injections up-dosing was evaluated by patients and physicians to be effective and well tolerated.